Synthetic Biology Market expected to hit USD 56.87 Bn by 2029 during the forecast period at a CAGR of 25.4 per - openPR
| BGT Stock | 0.04 0 2.44% |
Slightly above 62% of Bio Gene's investor base is looking to short. The analysis of overall sentiment of trading Bio Gene Technology stock suggests that many investors are alarmed at this time. Bio Gene's investing sentiment can be driven by a variety of factors including economic data, Bio Gene's earnings reports, geopolitical events, and overall market trends.
Bio |
Synthetic Biology Market expected to hit USD 56.87 Bn by 2029 during the forecast period at a CAGR of 25.4 per openPR
Read at news.google.com
 |
Bio Gene Fundamental Analysis
We analyze Bio Gene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Gene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Bio Gene is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Bio Gene Technology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bio Gene stock to make a market-neutral strategy. Peer analysis of Bio Gene could also be used in its relative valuation, which is a method of valuing Bio Gene by comparing valuation metrics with similar companies.
Peers
Bio Gene Related Equities
| PFG | Prime Financial | 4.35 | ||||
| BFL | BSP Financial | 0.62 | ||||
| PCI | Perpetual Credit | 0.85 | ||||
| MAF | MA Financial | 2.28 | ||||
| QBE | Qbe Insurance | 2.66 |
Additional Tools for Bio Stock Analysis
When running Bio Gene's price analysis, check to measure Bio Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Gene is operating at the current time. Most of Bio Gene's value examination focuses on studying past and present price action to predict the probability of Bio Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Gene's price. Additionally, you may evaluate how the addition of Bio Gene to your portfolios can decrease your overall portfolio volatility.